Aby J. Mathew Sells 404 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 404 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $10,916.08. Following the completion of the transaction, the executive vice president now directly owns 262,715 shares of the company’s stock, valued at approximately $7,098,559.30. The trade was a 0.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BioLife Solutions Trading Up 2.1 %

BLFS stock opened at $27.69 on Friday. BioLife Solutions, Inc. has a 12 month low of $14.50 and a 12 month high of $28.88. The firm’s 50-day moving average is $25.99 and its 200 day moving average is $24.29. The company has a market capitalization of $1.28 billion, a PE ratio of -26.12 and a beta of 1.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Wall Street Analysts Forecast Growth

BLFS has been the subject of several analyst reports. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday. HC Wainwright cut their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its holdings in shares of BioLife Solutions by 4.7% in the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after purchasing an additional 8,580 shares during the period. Barclays PLC raised its position in BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Geode Capital Management LLC raised its position in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares in the last quarter. State Street Corp lifted its holdings in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares during the period. Finally, Stifel Financial Corp grew its position in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.